IVERIC bio, Inc. Common Stock
ISEE
ISEE was delisted on the 10th of July, 2023.
52 hedge funds and large institutions have $21.2M invested in IVERIC bio, Inc. Common Stock in 2019 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 10 increasing their positions, 18 reducing their positions, and 11 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
10% less funds holding
Funds holding: 58 → 52 (-6)
10% less capital invested
Capital invested by funds: $23.7M → $21.2M (-$2.47M)
44% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 18
55% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$320K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$285K |
| 3 |
Renaissance Technologies
New York
|
+$169K |
| 4 |
BFM
Boothbay Fund Management
New York
|
+$128K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$117K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$309K |
| 2 |
SIM
Spark Investment Management
New York
|
-$265K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$243K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$167K |
| 5 |
Two Sigma Investments
New York
|
-$128K |
ISEE Hedge Fund Activity: Q2 2019 in Review
52 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in IVERIC bio, Inc. Common Stock (ISEE) for Q2 2019, worth a combined $21.2M — down 10% from $23.7M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of ISEE and 5 opened new positions — a net loss of 6 holders — while 18 trimmed existing stakes and 10 added.
The largest buyer was Assenagon Asset Management, opening a new position worth an estimated $320K. The largest seller was Morgan Stanley, cutting an estimated $309K.
- 52 institutional investors held IVERIC bio, Inc. Common Stock (ISEE) as of Q2 2019, down from 58 in Q1 2019.
- Funds reported $21.2M of IVERIC bio, Inc. Common Stock stock for Q2 2019, down 10% quarter-over-quarter.
- 5 funds opened new IVERIC bio, Inc. Common Stock positions in Q2 2019 and 11 closed out, a net change of -6 holders.
- The largest IVERIC bio, Inc. Common Stock buyer in Q2 2019 was Assenagon Asset Management, an estimated $320K added.
- The largest IVERIC bio, Inc. Common Stock seller in Q2 2019 was Morgan Stanley, an estimated $309K sold.
Based on aggregated 13F filings for Q2 2019.